Summit Healthcare (SMIH) Shareholders Approve YS Biopharma Deal
by Marlena Haddad on 2023-03-14 at 4:37pm

Summit Healthcare (NASDAQ:SMIH) announced that its shareholders have approved its combination with drug-maker YS Biopharma at a special meeting held earlier today.

The SPAC did not disclose redemption figures, but noted that the transaction is expected to deliver approximately $36 million in gross proceeds, which are expected to be used for the clinical development and future commercialization of the company’s vaccines.

The parties expect to officially close the deal on Thursday, March 16, 2023. YS Biopharma will remain as the combined company and its shares and warrants are expected to begin trading on the Nasdaq Capital Market under the symbols “YS” and “YSBPW,” respectively, on Friday, March 17, 2023.

Summit announced the $1 billion deal with YS Biopharma in September 2022. The Beijing-based company currently makes a rabies vaccine for the Chinese market and is working to commercialize a range of new vaccines and other treatments.

Upon closing of the transaction, Mr. Bo Tan, the CEO, Co-Chief Investment Officer, and director of Summit, will join YS Biopharma’s board of directors. The board of directors of YS Biopharma will consist of seven directors, including two current directors of YS Biopharma, Mr. Bo Tan, and four independent directors.


ADVISORS

  • Wilson Sonsini Goodrich & Rosati is serving as legal advisors to YS Biopharma
  • Jingtian & Gongcheng is serving as legal advisors to YS Biopharma
  • Maples Group is serving as legal advisors to YS Biopharma
  • Cooley LLP and Ogier are serving as legal advisors to Summit
Summit Healthcare (SMIH) Shareholders Approve YS Biopharma Deal
Recent Posts
by Nicholas Alan Clayton on 2025-07-11 at 8:24am

At the SPAC of Dawn Lately de-SPACs have been announcing corporate moves of a kind frequently in trios as was the case earlier this week when WeBull (NASDAQ:BULL), AST SpaceMobile (NASDAQ:ASTS) and Quantum-Si (NASDAQ:QSI) all announced major equity raises. This week, it is a trio of de-SPACs making reverse stock splits in unison, which is...

by Kristi Marvin on 2025-07-10 at 8:31am

A look at Plus’ software-first approach to autonomous trucking. After years of investment and excitement, the dawn of self-driving cars and trucks is now here. The question now is which business model among autonomous driving technology companies will win out? This week, we speak with David Liu, CEO of autonomous trucking company Plus. Plus announced...

by Nicholas Alan Clayton on 2025-07-10 at 8:27am

At the SPAC of Dawn One thing that SPAC investors can typically count on while their money is invested in a SPAC’s trust is that it is going to grow one way or the other between now and their next redemption opportunity, but the devil can occasionally be in the details. In 2024, it became...

by Nicholas Alan Clayton on 2025-07-09 at 12:57pm

Thunderstone has filed for a $50 million SPAC to put a new first-time Asia-based team in action on a generalist hunt. The new SPAC is offering investors a right to a 1/8 share in each unit with 18 months to initially complete a business combination. It is the 8th fresh S-1 filed with underwriter D....

by Nicholas Alan Clayton on 2025-07-09 at 8:22am

At the SPAC of Dawn In a trading session that may find itself built around the release of Fed minutes at 2 pm ET this afternoon, a pair of SPAC targets have added their own fresh information to the mix. Enterprise AI firm Fusemachines, which has a pending combination with CSLM (OTC:CSLMF), put out a...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved